Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 1/20 | 0.49 |
| ▸ | SMO | Q99835 | 2/20 | 0.48 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 3/20 | 0.42 |
| ▸ | HTR2B | P41595 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | NPY2R | P49146 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806265 | 0.94 | EIF2AK3 (0.48) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6809001 | 0.94 | EIF2AK3 (0.49) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6664835 | 0.91 | EIF2AK3 (0.46) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6668503 | 0.91 | EIF2AK3 (0.51) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6803784 | 0.91 | EIF2AK3 (0.53) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6804640 | 0.91 | SMO (0.50) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6809248 | 0.91 | SMO (0.56) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6804490 | 0.90 | EIF2AK3 (0.50) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| Hydrochloric Acid SCHEMBL6664580 | 0.90 | EIF2AK3 (0.50) | EIF2AK3SMOCREBBPHTR2CHTR2B | |
| SCHEMBL6798779 | 0.90 | EIF2AK3 (0.47) | EIF2AK3SMOCREBBPHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040157866-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-08-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157866-A1 | Amide compounds | APOB, NR1H2, NR1H3 | EIF2AK3 2638/4885SMO 4390/4885CREBBP 1901/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.